OPEN END TURBO LONG - BIOMARIN PHARMACEUTICAL Share Price

Certificat

DE000MG3C4W7

Market Closed - Börse Stuttgart 11:24:04 07/06/2024 pm IST
1 EUR +2.04% Intraday chart for OPEN END TURBO LONG - BIOMARIN PHARMACEUTICAL
Current month+117.39%
1 month-15.25%
Date Price Change
07/24/07 1 +2.04%
06/24/06 0.98 +12.64%
05/24/05 0.87 +8.75%
04/24/04 0.8 +40.35%
03/24/03 0.57 +23.91%

Delayed Quote Börse Stuttgart

Last update June 07, 2024 at 11:24 pm IST

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying BIOMARIN PHARMACEUTICAL INC.
Issuer Morgan Stanley
WKN MG3C4W
ISINDE000MG3C4W7
Date issued 30/04/2024
Strike 70.73 $
Maturity Unlimited
Parity 10 : 1
Emission price 1.04
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.41
Lowest since issue 0.33

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
-
More about the company

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BioMarin Pharmaceutical Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
80.69 USD
Average target price
108.1 USD
Spread / Average Target
+33.96%
Consensus